PDF(Pubmed)
Abstract：
BACKGROUND: Exudative retinal detachment with macular edema is one of the complications of retinitis pigmentosa (RP). In this report, we present a case who treated with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in RP-related exudative retinal detachment and subsequently improved with favorable outcome.
METHODS: A 49-year-old man, with a history of RP, had persistent blurred vision and was newly diagnosed with bilateral shallow exudative retinal detachment and macular edema.
METHODS: Fluorescein angiography showed bilateral diffuse dye leakage with macular pooling, and systemic survey excluded the possibility of infection or autoimmune disease.
METHODS: The patient was treated with intravitreal injection of aflibercept, one of the anti-VEGF agents, for bilateral eyes. Recurrent exudative retinal detachment and macular edema were noted, and repeated intravitreal injections of aflibercept in bilateral eyes were then arranged. Subsequently, bilateral macular edema and exudative retinal detachment subsided again, and the treatment course lasted for approximately 1 year.
RESULTS: After 1 year, the exudative retinal detachment with macular edema was much improved. In the meanwhile, visual functional improvement was also achieved.
CONCLUSIONS: This case illustrated the possibility of intravitreal injection of anti-VEGF therapy for the treatment of this rare complication of RP, and it may be a newly explored alternative treatment.
METHODS: A 49-year-old man, with a history of RP, had persistent blurred vision and was newly diagnosed with bilateral shallow exudative retinal detachment and macular edema.
METHODS: Fluorescein angiography showed bilateral diffuse dye leakage with macular pooling, and systemic survey excluded the possibility of infection or autoimmune disease.
METHODS: The patient was treated with intravitreal injection of aflibercept, one of the anti-VEGF agents, for bilateral eyes. Recurrent exudative retinal detachment and macular edema were noted, and repeated intravitreal injections of aflibercept in bilateral eyes were then arranged. Subsequently, bilateral macular edema and exudative retinal detachment subsided again, and the treatment course lasted for approximately 1 year.
RESULTS: After 1 year, the exudative retinal detachment with macular edema was much improved. In the meanwhile, visual functional improvement was also achieved.
CONCLUSIONS: This case illustrated the possibility of intravitreal injection of anti-VEGF therapy for the treatment of this rare complication of RP, and it may be a newly explored alternative treatment.
摘要：
背景：渗出性视网膜脱离伴黄斑水肿是视网膜色素变性（RP）的并发症之一。在这份报告中,我们介绍了一例玻璃体腔注射抗血管内皮生长因子(anti-VEGF)治疗RP相关性渗出性视网膜脱离的病例,随后得到改善,结局良好.
方法：一名49岁的男子，有RP的历史，持续视力模糊，新诊断为双侧浅层渗出性视网膜脱离和黄斑水肿。
方法：荧光素血管造影显示双侧弥漫性染料渗漏伴黄斑聚集，系统检查排除了感染或自身免疫性疾病的可能性。
方法：患者玻璃体内注射阿柏西普，抗VEGF药物之一，双侧眼睛。发现复发性渗出性视网膜脱离和黄斑水肿，然后安排在双侧眼中反复玻璃体内注射阿柏西普。随后，双侧黄斑水肿和渗出性视网膜脱离再次消退，疗程持续约1年。
结果：1年后，有黄斑水肿的渗出性视网膜脱离得到了很大改善。同时,视觉功能也得到了改善。
结论：该病例说明了玻璃体内注射抗VEGF治疗RP这种罕见并发症的可能性，这可能是一种新探索的替代疗法。
方法：一名49岁的男子，有RP的历史，持续视力模糊，新诊断为双侧浅层渗出性视网膜脱离和黄斑水肿。
方法：荧光素血管造影显示双侧弥漫性染料渗漏伴黄斑聚集，系统检查排除了感染或自身免疫性疾病的可能性。
方法：患者玻璃体内注射阿柏西普，抗VEGF药物之一，双侧眼睛。发现复发性渗出性视网膜脱离和黄斑水肿，然后安排在双侧眼中反复玻璃体内注射阿柏西普。随后，双侧黄斑水肿和渗出性视网膜脱离再次消退，疗程持续约1年。
结果：1年后，有黄斑水肿的渗出性视网膜脱离得到了很大改善。同时,视觉功能也得到了改善。
结论：该病例说明了玻璃体内注射抗VEGF治疗RP这种罕见并发症的可能性，这可能是一种新探索的替代疗法。
